1. $VRTX vs. $REGN vs. $BMRN vs. $INCY Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|REGN|BMRN|INCY|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  2. $BMRN vs. $PCYC vs. $VRTX vs. $INCY Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=BMRN|PCYC|VRTX|INCY|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  3. Equities tagged #pullback - $AOS $APOG $BAC $DPS $FDX $HMC $MNST $PEP $TM $VRTX https://closingbell.co/search?reason=pullback

  4. Insider Transaction: $VRTX Automatic Sale at $127.61 - $129.88 per share of 11700 shares by Director Boger Joshua S on 2015-04-15.

  5. $VRTX: New Insider Transaction on VRTX by Director BOGER JOSHUA S: http://insideri.com/1197023_000120919115035006_0001209191-15-035006

  6. Vertex Pharmaceuticals Incorporated director just cashed-in 11,700 options http://www.conferencecalltranscripts.org/4/summary2/?id=1620995 $VRTX

  7. $VRTX: New SEC Filing for VRTX: Form PRE 14A, No. 0000875320-15-000018 http://stocknewsflow.com/875320_000087532015000018_0000875320-15-000018

  8. Other preliminary proxy statements http://www.conferencecalltranscripts.org/no/summary2/?id=1620416 $VRTX

  9. $VRTX vs. $ALXN vs. $BMRN vs. $INCY Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|ALXN|BMRN|INCY|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  10. $VRTX vs. $BMRN vs. $REGN vs. $PCYC Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|BMRN|REGN|PCYC|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  11. $BMRN vs. $ALKS vs. $MDVN vs. $VRTX Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=BMRN|ALKS|MDVN|VRTX|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  12. $VRTX vs. $ALXN vs. $ALKS vs. $PCYC Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|ALXN|ALKS|PCYC|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  13. Insider Transaction: $VRTX Automatic Sale at $128.60 per share of 1125 shares by Officer Silva Paul M on 2015-04-13.

  14. Vertex Pharmaceuticals Incorporated s SVP & Corp Controller just cashed-in 1,125 options http://www.conferencecalltranscripts.org/4/summary2/?id=1614791 $VRTX

  15. $VRTX I have July 125 calls. Despite recent run up they haven t moved. Not sure why they are illiquid. Would have thot a nice gain by now

  16. $BMRN vs. $VRTX vs. $INCY vs. $MDVN Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=BMRN|VRTX|INCY|MDVN|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  17. $BMRN vs. $ALKS vs. $INCY vs. $VRTX Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=BMRN|ALKS|INCY|VRTX|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  18. @OphirGottlieb $VRTX vs. $PCYC vs. $INCY vs. $ALKS Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|PCYC|INCY|ALKS|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  19. $VRTX vs. $PCYC vs. $INCY vs. $ALKS Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|PCYC|INCY|ALKS|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  20. @Stockoptionexpert: $BIIB bearish put block added, weekly 425 put 1400 con, some of us are in- BIOTECH SECTOR ( $CLDX $GILD $VRTX)

  21. $BIIB bearish put block added, weekly 425 put 1400 con, some of us are in- BIOTECH SECTOR ( $cldx $gild $vrtx)

  22. $VRTX vs. $ALXN vs. $BMRN vs. $PCYC Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|ALXN|BMRN|PCYC|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  23. @OphirGottlieb: $VRTX vs. $ALXN vs. $PCYC vs. $INCY Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|ALXN|PCYC|INCY|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End) http://stocktwits.com/OphirGottlieb/message/35266761

  24. $VRTX vs. $ALXN vs. $PCYC vs. $INCY Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=VRTX|ALXN|PCYC|INCY|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  25. Is $VRTX a BUY? Salveen Richter thinks so:https://www.finstead.com/outlook/vrtx-vertex-pharmaceuticals-incorporated#recent-opinion